B7-33
Single-chain relaxin analog
A relaxin-derived peptide studied for anti-fibrotic signaling in cardiac, renal and pulmonary tissue models.
How it works
Acts as a biased agonist at RXFP1, favoring the ERK1/2 anti-fibrotic pathway over the cyclic AMP pathway, which reduces collagen deposition without the full vasodilatory profile of relaxin.
What research has shown
Animal models report reduced fibrosis in heart, kidney and lung tissue; no human trials are published.
Reported ranges in the literature
Low end
Animal model doses only
Optimal
No established human range
High end
Not characterized in humans
Frequency reported in the literature: Daily in reported animal protocols
Protocol duration and pairing
Typical study duration
2 to 8 week fibrosis models.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.